SEARCH

SEARCH BY CITATION

References

  • 1
    Australian Institute of Health and Welfare 2006. Maternal Deaths in Australia 2000–02. Available at http://www.aihw.gov.au/publications/index.cfm. Accessed 13 December 2007.
  • 2
    Kastner ES, Figueroa R, Garry D, Maulik D. Emergency peripartum hysterectomy: Experience at a community teaching hospital. Obstet Gynecol 2002; 99: 971975.
  • 3
    Smith J, Mousa HA. Peripartum hysterectomy for primary postpartum haemorrhage: Incidence and maternal morbidity. J Obstet Gynaecol 2007; 27: 4447.
  • 4
    Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004–06. Int J Gynaecol Obstet 2006; 94: 243253.
  • 5
    Macphail S, Fitzgerald J. Massive post-partum haemorrhage. Curr Obstet Gynaecol 2001; 11: 108114.
  • 6
    Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958965.
  • 7
    Key NS, Aledort LM, Beardsley D et al . Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912918.
  • 8
    Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464520.
  • 9
    Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9: S61S65.
  • 10
    Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542547.
  • 11
    Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – A European perspective. Crit Care 2006; 10: R120.
  • 12
    Shander A, Goodnough LT, Ratko T et al . Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharma Ther 2005; 30: 644.
  • 13
    Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 2005; 94: 592595.
  • 14
    Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, De Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: Case report and review of the literature. BJOG 2004, 111: 284287.
  • 15
    Bouwmeester FW, Jonkhoff AR, Verheijen RH, Van Geijn HP. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol 2003; 101: 11741176.
  • 16
    Segal S, Shemesh IY, Blumental R et al . The use of recombinant factor VIIa in severe postpartum hemorrhage. Acta Obstet Gynecol Scand 2004; 83: 771772.
  • 17
    Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007; 114: 815.
  • 18
    Ahonen J, Jokela R, Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand 2007; 51: 929936.
  • 19
    Monash Haemostasis Registry. Available at http://www.med.monash.edu.au/epidemiology/traumaepi/haemostasis.html. Accessed 13 December 2007.
  • 20
    Loudon B, Smith MP. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: A pharmacoeconomic evaluation. Intern Med J 2005; 35: 463467.